Transfusion requirement can be abolished by epoietin-α and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support

L. Ponchio, A. Zambelli, A. De Stefano, F. S. Robustelli della Cuna, C. Perotti, P. Pedrazzoli

Research output: Contribution to journalArticle


In patients undergoing high dose sequential chemotherapy (HDS) for breast cancer (BC), allogeneic platelet transfusions can be avoided by using cryopreserved autologous platelets. Nevertheless, half of these patients develop a mild anemia before myeloblation, requiring eventually blood transfusion. In this cohort of patients, we evaluated the efficacy of recombinant human erythropoietin (EPO) in preventing the development of anemia, and therefore any allogeneic transfusion requirement.

Original languageEnglish
Pages (from-to)219-220
Number of pages2
Issue number2
Publication statusPublished - 2000



  • Autologous transplantation
  • Epoetin-α
  • High-dose chemotherapy
  • Red blood cell transfusion

ASJC Scopus subject areas

  • Hematology

Cite this